naftifine

Trade name: naftin

Small moleculeapproved

Approved

Feb 29, 1988

Naftifine is a synthetic, broad spectrum, antifungal agent and allylamine derivative. The following in vitro data are available, but their clinical significance is unknown. Naftifine has been shown to exhibit fungicidal activity in vitro against a broad spectrum of organisms including Trichophyton rubrum, Trichophyton mentagrophytes, Trichophyton tonsurans, Epidermophyton floccosum, and Microsporum canis, Microsporum audouini, and Microsporum gypseum; and fungistatic activity against Candida species including Candida albicans. However it is only used to treat the organisms listed in the indications. Although the exact mechanism of action against fungi is not known, naftifine appears to interfere with sterol biosynthesis by inhibiting the enzyme squalene 2,3-epoxidase. This inhibition of enzyme activity results in decreased amounts of sterols, especially ergosterol, and a corresponding accumulation of squalene in the cells. Naftifine is used for the topical treatment of tinea pedis, tinea cruris, and tinea corporis caused by the organisms Trichophyton rubrum, Trichophyton mentagrophytes, Trichophyton tonsurans and Epidermophyton floccosum. Marketed as Naftin. — NCATS

Clinical trial activity

16 trials · 7 clinical orgs · 7 marketing orgs

Phase 1
4
Phase 2
9
Phase 3
6
Phase 4
3

Earliest trial started Sep 1, 2005 (NCT00253305)

Timeline

1980s

  1. Feb 29, 1988

    Earliest FDA Approval

  2. Feb 29, 1988

    Sebela Pharmaceuticals — NDA Secondary Org

  3. Feb 29, 1988

    LEGACY PHARMA — Marketing Organization

1990s

  1. Jun 18, 1990

    Sebela Pharmaceuticals — First NDA Organization

  2. Jun 18, 1990

    Sebela Pharmaceuticals — NDA Organization

2000s

  1. Jan 1, 2005

    Earliest Phase 2 Sponsor(trial)

  2. Jan 1, 2008

    Earliest Phase 3 Sponsor(trial)

2010s

  1. Jan 1, 2012

    Taro Pharmaceuticals — Earliest Phase 1 Sponsor(trial)

  2. Jan 6, 2016

    Taro Pharmaceuticals — Marketing Organization

  3. Jan 6, 2016

    Sun Pharmaceuticals — Marketing Organization

  4. Apr 10, 2017

    Amneal Pharmaceuticals — Marketing Organization

  5. Apr 10, 2017

    Tolmar Inc. — Marketing Organization

2020s

  1. Sep 22, 2020

    Exeltis — Marketing Organization

Indications

Mechanism of action

Approval history

  • approvedFeb 29, 1988

Chemistry & pharmacology

Loading structure…

SMILES

CN(C/C=C/c1ccccc1)Cc1cccc2ccccc12
Mol. weight
287.41 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Achiral Molecule
Inorganic
No
Polymer
No
Delivery
Topical
Availability
Prescription Only

Oral

No

Parenteral

No

Topical

Yes

Sources

Also known as

  • 1-naphthalenemethanamine, n-methyl-n-(3-phenyl-2-propenyl)-, (e)-
  • aw-105843
  • aw-105843
  • aw-105-843
  • aw-105-843
  • exoderil
  • exoderil
  • naftifin
  • naftifin
  • naftifin
  • naftifin
  • naftifina
  • naftifina
  • naftifine
  • naftifine
  • naftifine
  • naftifine
  • naftifine
  • naftifine
  • naftifine
  • naftifine
  • naftifine
  • naftifine
  • naftifine hcl
  • naftifine hcl
  • naftifine hcl
  • naftifine hydrochloride
  • naftifine hydrochloride
  • naftifine hydrochloride
  • naftifine hydrochloride
  • naftifine hydrochloride
  • naftifine hydrochloride, (e)-isomer
  • naftifinum
  • naftifinum
  • naftifungin
  • naftin
  • naftin
  • naftin
  • naftin
  • n-cinnamyl-n-methyl-1-naphthalenemethylamine hydrochloride

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT05363449Phase 1Feb 17, 2022Therapeutics, Inc.
NCT03897257Phase 2Mar 15, 2019Therapeutics, Inc.
NCT02658292Phase 2Jan 12, 2016Merz
NCT02633813Phase 3Mar 1, 2015Catawba Clinical Research, Genzum Life Sciences
NCT02227290Phase 4Aug 1, 2014Merz
NCT02335255Phase 1Jun 1, 2014Catawba Clinical Research, Taro Pharmaceuticals
NCT02466867Phase 4Jan 1, 2014Merz
NCT02132260Phase 1Aug 1, 2013Catawba Clinical Research, Taro Pharmaceuticals
NCT01885156Phase 3Aug 1, 2013Merz
NCT01712360Phase 4Oct 1, 2012Merz
NCT01580891Phase 1May 1, 2012Taro Pharmaceuticals
NCT01290341Phase 3Feb 1, 2011Merz, Paddington Testing Company
NCT01289015Phase 3Feb 1, 2011Merz, Paddington Testing Company
NCT00750152Phase 3Sep 1, 2008Merz, Paddington Testing Company
NCT00750139Phase 3Aug 1, 2008Merz, Paddington Testing Company
NCT00253305Phase 2Sep 1, 2005MediQuest Therapeutics
Showing 16 of 16 trials
Page 1 / 1

Organizations

Research & Development (7)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
MerzFor profit9932008
Paddington Testing CompanyFor profit4012008
Catawba Clinical ResearchFor profit3022013
Taro PharmaceuticalsFor profit3312012
Therapeutics, Inc.For profit2222019
Genzum Life SciencesFor profit1112015
MediQuest TherapeuticsFor profit1112005
7 organizations
Page 1 / 1

Marketing (9)

OrganizationOrg typeRelationshipDate
Amneal PharmaceuticalsFor profitMKTGApr 10, 2017
ExeltisFor profitMKTGSep 22, 2020
LEGACY PHARMAFor profitMKTGFeb 29, 1988
Sebela PharmaceuticalsFor profitNDAJun 18, 1990
Sebela PharmaceuticalsFor profitNDA2Feb 29, 1988
Sun PharmaceuticalsFor profitMKTGJan 6, 2016
Taro PharmaceuticalsFor profitMKTGJan 6, 2016
Taro PharmaceuticalsFor profitSYNApr 10, 2019
Tolmar Inc.For profitMKTGApr 10, 2017